Theralase Technologies Inc (TLTFF)

[123414]

Low dose is half dose .35(therapeutic in preclin) next dose is .70.

The study will consist of 2 phases. In the first phase, 3 subjects will receive PDT (TLC-3200 System) employing 0.35 mg/cm^2 (maximum recommended starting dose) TLD1433. If treatment with the maximum recommended starting dose does not raise significant safety concerns as determined by the safety monitoring committee, an additional 6 subjects will receive PDT with 0.70 mg/cm^2 (therapeutic dose) TLD1433.
https://clinicaltrials.gov/ct2/show/NCT03053635?term=1433&rank=1

Here is something that is interesting... The CEO has said the .35 mg dose was therapeutic back in January. However it evidently was therapeutic in the preclinical rat test. So when clinicaltrials.gov listed the dosages they only listed the .70 as theraputic (our next 6 patients) because they have not proven in humans the .35 dose is therapeutic.

TS 1:43 CEO "in that clinical study that's being conducted at UHN that's one of the top two cancer facilities in the world...with this study we're enrolling 3 patients and treating them at a low dose which is the therapeutic dose.

http://www.kereport.com/2017/01/17/date-theralase-beginning-phase-1b-clinical-trial/